Neurocrine Biosciences logo

Neurocrine Biosciences Share Price Today

(NASDAQ: NBIX)

Neurocrine Biosciences share price is $151.2 & ₹13,219.42 as on 6 Feb 2025, 2.30 'hrs' IST

$151.2

-1.22

(-0.8%)

Market is closed - opens 8 PM, 06 Feb 2025

View live Neurocrine Biosciences share price in Dollar and Rupees. Guide to invest in Neurocrine Biosciences stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Neurocrine Biosciences, along with analyst recommendations, forecasts, and comprehensive financials.

Neurocrine Biosciences share price movements

  • Today's Low: $150.74
    Today's High: $153.09

    Day's Volatility :1.53%

  • 52 Weeks Low: $110.95
    52 Weeks High: $157.98

    52 Weeks Volatility :29.77%

Neurocrine Biosciences (NBIX) Returns

PeriodNeurocrine Biosciences Inc.Sector (Health Care)Index (Russel 2000)
3 Months
21.96%
0.3%
0.0%
6 Months
3.05%
0.6%
0.0%
1 Year
10.94%
3.1%
0.0%
3 Years
86.62%
12.2%
-11.7%

Neurocrine Biosciences (NBIX) Key Statistics

in dollars & INR

Previous Close
$152.42
Open
$151.68
Today's High
$153.0893
Today's Low
$150.74
Market Capitalization
$15.3B
Today's Volume
$1.4M
52 Week High
$157.9799
52 Week Low
$110.95
Revenue TTM
$2.2B
EBITDA
$628.0M
Earnings Per Share (EPS)
$3.75
PE Ratio
40.32
Profit Margin
17.21%
Quarterly Earnings Growth YOY
0.51%
Return On Equity TTM
16.35%

How to invest in Neurocrine Biosciences Stock (NBIX) from India?

It is very easy for Indian residents to invest directly in Neurocrine Biosciences from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Neurocrine Biosciences stock in both Indian Rupees (INR) and US Dollars (USD). Search for Neurocrine Biosciences or NBIX on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Neurocrine Biosciences or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Neurocrine Biosciences shares which would translate to 0.006 fractional shares of Neurocrine Biosciences as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Neurocrine Biosciences, in just a few clicks!

Returns in Neurocrine Biosciences (NBIX) for Indian investors in Rupees

The Neurocrine Biosciences stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Neurocrine Biosciences investment value today

Current value as on today

₹1,16,308

Returns

₹16,308

(+16.31%)

Returns from Neurocrine Biosciences Stock

₹10,940 (+10.94%)

Dollar Returns

₹5,368 (+5.37%)

Indian investors sentiment towards Neurocrine Biosciences (NBIX)

60%

Period: Jan 6, 2025 to Feb 5, 2025. Change in 30 Days versus previous period

Search interest for Neurocrine Biosciences Stock from India on INDmoney has increased by 60% in the last 30 days, reflecting an upward trend in search activity.

Global Institutional Holdings in Neurocrine Biosciences

  • BlackRock Inc

    14.08%

  • Vanguard Group Inc

    9.87%

  • State Street Corp

    5.08%

  • JPMorgan Chase & Co

    2.96%

  • Renaissance Technologies Corp

    2.54%

  • Bellevue Group AG

    1.84%

Analyst Recommendation on Neurocrine Biosciences

Buy

    76%Buy

    23%Hold

    0%Sell

Based on 34 Wall street analysts offering stock ratings for Neurocrine Biosciences(by analysts ranked 0 to 5 stars)

Based on 34 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
26
26
25
Hold
8
9
9
Sell
0
0
0

Analyst Forecast on Neurocrine Biosciences Stock (NBIX)

What analysts predicted

Upside of 12.85%

Target:

$170.63

Current:

$151.20

Insights on Neurocrine Biosciences Stock (Ticker Symbol: NBIX)

  • Price Movement

    In the last 3 years, NBIX stock has moved up by 86.3%
  • Increasing Revenue

    Revenue is up for the last 11 quarters, 310.6M → 622.1M (in $), with an average increase of 6.6% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, 43.4M → 129.8M (in $), with an average increase of 41.6% per quarter
  • NBIX vs ITCI (1 yr)

    In the last 1 year, Intra-cellular Therapies, Inc. has given 81.2% return, outperforming this stock by 75.4%
  • NBIX vs ITCI (3 yr)

    In the last 3 years, Intra-cellular Therapies, Inc. has given 160.7% return, outperforming this stock by 74.4%
  • Price to Sales

    ForNBIX every $1 of sales, investors are willing to pay $6.7, whereas for Intra-cellular Therapies, Inc., the investors are paying $20.8 for every $1 of sales.

NBIX Neurocrine Biosciences Financials in INR & Dollars

FY18Y/Y Change
Revenue
$451.2M
↑ 179.19%
Net Income
$21.1M
↓ 114.81%
Net Profit Margin
4.68%
↑ 92.87%
FY19Y/Y Change
Revenue
$788.1M
↑ 74.65%
Net Income
$37.0M
↑ 75.26%
Net Profit Margin
4.69%
↑ 0.01%
FY20Y/Y Change
Revenue
$1.0B
↑ 32.71%
Net Income
$407.3M
↑ 1000.81%
Net Profit Margin
38.94%
↑ 34.25%
FY21Y/Y Change
Revenue
$1.1B
↑ 8.38%
Net Income
$89.6M
↓ 78.0%
Net Profit Margin
7.9%
↓ 31.04%
FY22Y/Y Change
Revenue
$1.5B
↑ 31.34%
Net Income
$154.5M
↑ 72.43%
Net Profit Margin
10.38%
↑ 2.48%
FY23Y/Y Change
Revenue
$1.9B
↑ 26.76%
Net Income
$249.7M
↑ 61.62%
Net Profit Margin
13.23%
↑ 2.85%
Q2 FY23Q/Q Change
Revenue
$452.7M
↑ 7.68%
Net Income
$95.5M
↓ 224.67%
Net Profit Margin
21.1%
↑ 39.32%
Q3 FY23Q/Q Change
Revenue
$498.8M
↑ 10.18%
Net Income
$83.1M
↓ 12.98%
Net Profit Margin
16.66%
↓ 4.44%
Q4 FY23Q/Q Change
Revenue
$515.2M
↑ 3.29%
Net Income
$147.7M
↑ 77.74%
Net Profit Margin
28.67%
↑ 12.01%
Q1 FY24Q/Q Change
Revenue
$515.3M
↑ 0.02%
Net Income
$43.4M
↓ 70.62%
Net Profit Margin
8.42%
↓ 20.25%
Q2 FY24Q/Q Change
Revenue
$590.2M
↑ 14.54%
Net Income
$65.0M
↑ 49.77%
Net Profit Margin
11.01%
↑ 2.59%
Q3 FY24Q/Q Change
Revenue
$622.1M
↑ 5.4%
Net Income
$129.8M
↑ 99.69%
Net Profit Margin
20.86%
↑ 9.85%
FY18Y/Y Change
Profit
$446.4M
↑ 178.32%
FY19Y/Y Change
Profit
$780.7M
↑ 74.91%
FY20Y/Y Change
Profit
$1.0B
↑ 32.68%
FY21Y/Y Change
Profit
$1.1B
↑ 8.05%
FY22Y/Y Change
Profit
$1.5B
↑ 30.94%
FY23Y/Y Change
Profit
$1.8B
↑ 26.06%
Q2 FY23Q/Q Change
Profit
$441.2M
↑ 7.11%
Q3 FY23Q/Q Change
Profit
$487.6M
↑ 10.52%
Q4 FY23Q/Q Change
Profit
$506.7M
↑ 3.92%
Q1 FY24Q/Q Change
Profit
$502.5M
↓ 0.83%
Q2 FY24Q/Q Change
Profit
$574.6M
↑ 14.35%
Q3 FY24Q/Q Change
Profit
$614.1M
↑ 6.87%
FY18Y/Y Change
Operating Cash Flow
$101.4M
↓ 207.46%
Investing Cash Flow
$-242.9M
↓ 3.17%
Financing Cash Flow
$29.5M
↓ 94.28%
FY19Y/Y Change
Operating Cash Flow
$152.1M
↑ 50.01%
Investing Cash Flow
$-211.1M
↓ 13.11%
Financing Cash Flow
$27.3M
↓ 7.51%
FY20Y/Y Change
Operating Cash Flow
$228.5M
↑ 50.28%
Investing Cash Flow
$4.1M
↓ 101.94%
Financing Cash Flow
$-157.8M
↓ 677.75%
FY21Y/Y Change
Operating Cash Flow
$256.5M
↑ 12.25%
Investing Cash Flow
$-130.2M
↓ 3275.61%
Financing Cash Flow
$27.4M
↓ 117.36%
FY22Y/Y Change
Operating Cash Flow
$339.4M
↑ 32.32%
Investing Cash Flow
$-177.1M
↑ 36.02%
Financing Cash Flow
$-234.3M
↓ 955.11%
Q2 FY23Q/Q Change
Operating Cash Flow
$179.6M
↓ 243.45%
Investing Cash Flow
$-125.9M
↑ 199.05%
Financing Cash Flow
$2.9M
↓ 64.63%

Neurocrine Biosciences Technicals Summary

Sell

Neutral

Buy

Neurocrine Biosciences is currently in a neutral trading position according to technical analysis indicators.

Neurocrine Biosciences (NBIX) Vs Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Neurocrine Biosciences Inc. logo
9.92%
3.05%
10.94%
86.62%
42.65%
Intra-cellular Therapies, Inc. logo
52.63%
70.69%
85.26%
149.23%
494.99%
Haleon Plc Spon Ads logo
1.8%
0.1%
15.05%
29.96%
29.96%
Zoetis Inc. logo
7.45%
-6.71%
-10.87%
-12.31%
23.23%
Viatris Inc. logo
-8.75%
-9.5%
-6.73%
-28.24%
-32.99%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Neurocrine Biosciences Inc. logo
40.32
40.32
0.35
6.58
0.16
0.12
NA
26.87
Intra-cellular Therapies, Inc. logo
NA
NA
0.0
-0.71
-0.1
-0.07
NA
10.8
Haleon Plc Spon Ads logo
28.85
28.85
1.68
0.36
0.07
0.04
0.02
1.82
Zoetis Inc. logo
33.02
33.02
2.73
5.89
0.47
0.15
0.01
11.59
Viatris Inc. logo
224.4
NA
0.07
2.68
-0.04
0.02
0.04
16.58
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Neurocrine Biosciences Inc. logo
Buy
$15.3B
42.65%
40.32
17.21%
Intra-cellular Therapies, Inc. logo
Buy
$13.5B
494.99%
NA
-14.07%
Haleon Plc Spon Ads logo
Buy
$43.0B
29.96%
28.85
10.75%
Zoetis Inc. logo
Buy
$79.3B
23.23%
33.02
26.55%
Viatris Inc. logo
Hold
$13.0B
-32.99%
224.4
-5.87%

About Neurocrine Biosciences

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL " Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.
Organization
Neurocrine Biosciences
Employees
1700
CEO
Mr. Kyle W. Gano Ph.D.
Industry
Health Technology

Management People of Neurocrine Biosciences

NameTitle
Mr. Kyle W. Gano Ph.D.
CEO & Director
Mr. Matthew C. Abernethy CPA
Chief Financial Officer
Dr. Jude Onyia Ph.D.
Chief Scientific Officer
Dr. Eiry Wyn Roberts M.D.
Chief Medical Officer
Dr. Wylie W. Vale Ph.D.
Co-Founder
Dr. Lawrence Steinman BA, M.D., Ph.D.
Co-Founder of Neurocrine
Jane Sorensen
Head of Investor Relations
Mr. Darin M. Lippoldt Esq.
Chief Legal Officer & Corporate Secretary
Ms. Julie S. Cooke
Chief Human Resources Officer
Mr. Eric S. Benevich
Chief Commercial Officer

Important FAQs about investing in NBIX Stock from India :

What is Neurocrine Biosciences share price today?

Neurocrine Biosciences share price today stands at $151.20, Open: $151.68 ; Previous Close: $152.42 ; High: $153.09 ; Low: $150.74 ; 52 Week High: $157.98 ; 52 Week Low: $110.95.

The stock opens at $151.68, after a previous close of $152.42. The stock reached a daily high of $153.09 and a low of $150.74, with a 52-week high of $157.98 and a 52-week low of $110.95.

Can Indians buy Neurocrine Biosciences shares?

Yes, Indians can invest in the Neurocrine Biosciences (NBIX) from India.

With INDmoney, you can buy Neurocrine Biosciences at 0 brokerage. The step-by-step process is as follows:

  • Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
  • Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
  • Once funds are transferred successfully, you can buy Neurocrine Biosciences at zero transaction cost.

How can I buy Neurocrine Biosciences shares from India?

It is very easy to buy Neurocrine Biosciences from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Neurocrine Biosciences (NBIX) be purchased?

Yes, you can buy fractional shares of Neurocrine Biosciences with INDmoney app.

What are the documents required to start investing in Neurocrine Biosciences stocks?

To start investing in Neurocrine Biosciences, You will need the following documents:

  • Proof of Identification (PAN, Aadhaar etc)
  • Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.

What are today’s High and Low prices of Neurocrine Biosciences Stock (NBIX)?

Today’s highest price of Neurocrine Biosciences (NBIX) is $153.09.

Today’s lowest price of Neurocrine Biosciences (NBIX) is $150.74.

What is today's market capitalisation of Neurocrine Biosciences?

Today's market capitalisation of Neurocrine Biosciences NBIX is 15.3B

What is the 52 Week High and Low Range of Neurocrine Biosciences Stock (NBIX)?

  • 52 Week High

    $157.98

  • 52 Week Low

    $110.95

What are the historical returns of Neurocrine Biosciences (NBIX)?

  • 1 Month Returns

    9.92%

  • 3 Months Returns

    3.05%

  • 1 Year Returns

    10.94%

  • 5 Years Returns

    42.65%

Who is the Chief Executive Officer (CEO) of Neurocrine Biosciences ?

Mr. Kyle W. Gano Ph.D. is the current Chief Executive Officer (CEO) of Neurocrine Biosciences.